Company Listing
CRISPR Therapeutics

CRISPR Therapeutics is an early-stage biopharmaceutical company created to translate CRISPR-Cas9, a breakthrough gene-editing technology, into transformative medicines for the treatment of serious human diseases. CRISPR has formed the largest gene editing collaboration announced to date with Vertex Pharmaceuticals. The deal, worth up to $2.6 billion, will use CRISPR’s gene editing technology to discover and develop new treatments for genetic diseases.The company is working on translational development programmes in several important disease areas with collaborators in Europe and the US. CRISPR went public in October 2016.

 

BACK
Location
Basel, Switzerland and Cambridge, MA, USA
CEO
Rodger Novak
Abingworth Partner
Kurt von Emster
Website Address

Home

About Us

  1. About Us
  2. Our Team
  3. Transatlantic Reach
  4. Funds

Strategy

  1. Our Strategy
  2. Venture Capital
  3. Clinical Co‑development
  4. VIPEs
  5. Public Markets

Portfolio

  1. Portfolio Companies
  2. Case Studies

Media Centre

  1. Recent News
  2. Archived News
  3. Film

Contact

  1. Contact Us
  2. Send Us Your Proposal
Company Listing

CRISPR Therapeutics is an early-stage biopharmaceutical company created to translate CRISPR-Cas9, a breakthrough gene-editing technology, into transformative medicines for the treatment of serious human diseases. CRISPR has formed the largest gene editing collaboration announced to date with Vertex Pharmaceuticals. The deal, worth up to $2.6 billion, will use CRISPR’s gene editing technology to discover and develop new treatments for genetic diseases.The company is working on translational development programmes in several important disease areas with collaborators in Europe and the US. CRISPR went public in October 2016.

 

Location
Basel, Switzerland and Cambridge, MA, USA
CEO
Rodger Novak
Abingworth Partner
Kurt von Emster
Website Address
BACK
 
Copyright Abingworth 2017